IN8BIO, INC. (INAB) - Q2 2024 Filing Summary
Business Context and Reporting Period
Company: IN8BIO, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell product candidates for solid and liquid tumors. The company has no commercial product revenue and relies on equity financing. Key programs include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for hematologic malignancies).
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8,629) | $(7,715) | $(17,191) | $(15,240) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.27) | $(0.39) | $(0.57) |
| Operating Expenses | $8,689 | $7,715 | $17,334 | $15,570 |
| Cash and Restricted Cash (End of Period) | $10,476 | $17,246 | $10,476 | $17,246 |
| Accumulated Deficit | $(108,410) | $(76,452) | $(108,410) | $(76,452) |
Liquidity: As of June 30, 2024, the company held $10.2 million in cash. Management projects this will fund operations only into January 2025.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by $1.95 million compared to the prior year period, driven primarily by higher Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses rose $1.54 million year-over-year (YTD) to $10.1 million. This increase was attributed to a $1.0 million rise in personnel costs (salaries and stock-based compensation) and a $0.6 million increase in direct clinical costs for INB-100, INB-200, and INB-400.
- Cash Burn: Net cash used in operating activities was $14.0 million for the six months ended June 30, 2024, compared to $12.8 million in the prior year period.
- Financing Activity: The company raised approximately $3.5 million in net proceeds from the sale of common stock under its At-The-Market (ATM) program during the first half of 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for 12 months from the date of issuance due to recurring losses and negative cash flows. Additional capital is required to fund operations beyond January 2025.
- Capital Raising Plans: Management plans to raise additional capital through equity/debt offerings (including the ATM program) and strategic collaborations. Potential proceeds from outstanding warrants include up to $14.8 million from Series A warrants and up to $17.7 million from Series B warrants, though exercise is not guaranteed.
- Clinical Progress:
- INB-400: Phase 2 trial for newly diagnosed glioblastoma is ongoing. Preliminary data from an investigator-initiated trial presented at ASCO 2024 showed 92% of evaluable patients exceeded the median progression-free survival of standard-of-care therapy.
- INB-100: Phase 1 trial for high-risk leukemias has completed primary enrollment. Updated data presented at EHA 2024 showed 100% of evaluable patients remained alive and in durable complete remission through one year.
- Nasdaq Compliance: The company received notice on August 6, 2024, of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to the closing bid price falling below $1.00 per share for 31 consecutive days. The company has 180 days to regain compliance.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure funding before January 2025 to avoid operational delays or termination.
- Warrant Exercise: Assess the likelihood of Series A and Series B warrant holders exercising their options to provide the projected $32.5 million in potential proceeds.
- Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid delisting from the Nasdaq Stock Market.
- Clinical Milestones: Track upcoming data releases for INB-400 and INB-100 in the second half of 2024 and 2025, which are critical for future financing and valuation.
- ATM Program Capacity: Note that $31.1 million remains available under the ATM program, but the company is subject to "baby shelf" rules limiting primary offerings to one-third of public float due to a public float under $75 million.